Windlas Biotech
- Market cap
- ₹ 1,859 Cr.
- P/E
- 27.1x
- P/B
- 3.27x
- 52-week range
- 697.4 – 1,181.9
- ROE
- 12%
- ROCE
- 16%
- Dividend yield
- 0.7%
- Debt / equity
- 0.06
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Windlas Biotech Limited is a domestic pharmaceutical formulations contract development and manufacturing organization (CDMO). Its portfolio of CDMO solutions includes product development, licensing, and commercial manufacturing of complex drugs and dosage forms. Its product development and manufacturing capabilities in complex generic products by developing products, including alternate dosages, such as, medicated mouth sprays; coating technologies, including, pellet coating using bottom spray, API coating, pH dependent coating and nanosized crystals; nutraceuticals dosages, including, biscuits, protein powder, supplements, chocolate bars and malt based foods, and ayurvedic products, such as wellness products, hair oils and cough syrups. Its four fungible, Schedule-M compliant OSD/OLD manufacturing facilities are located in Dehradun, Uttarakhand, India. It specializes in manufacturing formulations, solid pharmaceutical dosage forms, liquid pharmaceutical dosage forms and injectables.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Windlas Biotech against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)27.1 against a typical 34: cheaper than most peers (1st = cheapest).90th of 220
- Sales growth+18.1% against a typical +15.6% from a year earlier.89th of 197
- Profit growth0% against a typical +18.9% from a year earlier.102nd of 160
- Share price, 3 months+3.8% against a typical −0.5%.74th of 200
- Size₹ 1,859 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).75th of 199
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Adequate safety
Rated A+ by ICRA- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| ICRA | [ICRA]A+ /[ICRA]A1+ | Stable | 29 Jun 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 29 Jun 2026 | Reaffirmed | [ICRA]A+ /[ICRA]A1+ | — | ICRA | ₹ 84.9 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 10 Aug 2026 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2026 |
| 21 May 2026 | Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2026 and dividend |
| 17 Apr 2026 | Buyback | To consider buyback for equity shares |
| 5 Feb 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 6 Nov 2025 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 |
| 12 Aug 2025 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2025 |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 153 | 162 | 171 | 175 | 187 | 195 | 203 | 210 | 222 | 233 | 238 | 248 |
| Expenses | 134 | 142 | 149 | 154 | 164 | 170 | 177 | 184 | 194 | 209 | 213 | 221 |
| Operating Profit | 19 | 20 | 22 | 21 | 23 | 25 | 26 | 27 | 29 | 24 | 25 | 27 |
| OPM % | 12% | 13% | 13% | 12% | 12% | 13% | 13% | 13% | 13% | 10% | 11% | 11% |
| Other Income | 3 | 3 | 4 | 4 | 5 | 4 | 5 | 5 | 4 | 5 | 4 | 5 |
| Interest | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 |
| Depreciation | 3 | 3 | 4 | 6 | 6 | 7 | 8 | 7 | 8 | 8 | 8 | 7 |
| Profit before tax | 18 | 20 | 23 | 18 | 20 | 20 | 21 | 23 | 24 | 20 | 20 | 23 |
| Tax % | 23% | 24% | 25% | 26% | 23% | 24% | 22% | 24% | 25% | 25% | 21% | 23% |
| Net Profit | 14 | 15 | 17 | 13 | 16 | 15 | 16 | 18 | 18 | 15 | 16 | 18 |
| EPS in Rs | 6.75 | 7.26 | 8.15 | 6.45 | 7.49 | 7.29 | 7.77 | 8.43 | 8.45 | 7.09 | 7.59 | 8.55 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 13%
- 5 Years
- 16%
- 3 Years
- 21%
- TTM
- 19%
- 10 Years
- 31%
- 5 Years
- 28%
- 3 Years
- 17%
- TTM
- 2%
- 10 Years
- —
- 5 Years
- 22%
- 3 Years
- 37%
- TTM
- —
- 10 Years
- 12%
- 5 Years
- 12%
- 3 Years
- 13%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Windlas Biotech | ₹ 891.00 | ₹ 1,859 Cr. | 27.1x | 3.3x | 12% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Prices are delayed and for information only. Nothing on this page is investment advice.